NVAX Novavax Inc.

7.84
+1.22  (+18%)
Previous Close 6.62
Open 6.78
Price To Book -1.22
Market Cap 187,551,036
Shares 23,922,326
Volume 5,611,062
Short Ratio
Av. Daily Volume 882,737

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated during fall of 2019. Top-line data due 1Q 2020.
NanoFlu vaccine
Influenza
Phase 2 safety and immunogenicity data released July 24, 2017 - efficacy trial to be initiated 2018.
RSV F Vaccine immunogenicity trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 3 released September 15, 2016 did not demonstrate efficacy.
RSV vaccine - Resolve trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 2 data released September 15, 2016.
RSV F Vaccine rollover trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 3 top-line data released March 28, 2019 - primary endpoint not met. Noted June 10, 2019 that a further Phase 3 trial is required.
RSV vaccine - prepare trial
Respiratory Syncytial Virus (RSV) in healthy pregnant women - protect infants via maternal immunization
Further Phase 2 trials planned
Seasonal Influenza Vaccine
Seasonal Flu

Latest News

  1. Why Novavax Stock Is Soaring Today
  2. 4 ‘Strong Buy’ Stocks to Follow Amid Recession Fears
  3. Implied Volatility Surging for Novavax (NVAX) Stock Options
  4. Options Traders Take Chance on NVAX Stock After Big Analyst Call
  5. New RSV vaccine data could boost Novavax as it searches for pathway to market
  6. The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results
  7. New Data from Novavax Phase 3 Prepare™ Trial of ResVax™ Presented at 2019 IDSOG Annual Meeting
  8. Edited Transcript of NVAX earnings conference call or presentation 7-Aug-19 8:30pm GMT
  9. Novavax Inc (NVAX) Q2 2019 Earnings Call Transcript
  10. Novavax Scientific Leadership to Present New RSV Maternal Immunization Program Phase 3 Data and Participate in Discussion on RSV at the 2019 IDSOG Annual Meeting
  11. Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates
  12. Novavax looks to next flu vaccine trial following sale of manufacturing business
  13. Novavax Reports Second Quarter 2019 Financial Results
  14. Germantown biopharma regains compliance with Nasdaq
  15. The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering
  16. Novavax Reaches Agreement with the FDA on Pivotal Phase 3 Trial Design for NanoFlu
  17. Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 7, 2019
  18. Novavax and Catalent Announce Closing of Strategic Partnership
  19. Germantown stem cell therapy company proposes $7M offering amid delisting threat
  20. What Kind Of Shareholders Own Novavax, Inc. (NASDAQ:NVAX)?